1
|
Roche N, Scheuch G, Pritchard JN, Nopitsch-Mai C, Lakhani DA, Saluja B, Jamieson J, Dundon A, Wallace R, Holmes S, Cipolla D, Dolovich MB, Shah SA, Lyapustina S. Patient Focus and Regulatory Considerations for Inhalation Device Design: Report from the 2015 IPAC-RS/ISAM Workshop. J Aerosol Med Pulm Drug Deliv 2016; 30:1-13. [PMID: 27537608 DOI: 10.1089/jamp.2016.1326] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
This article reports on discussions at the 2015 workshop cosponsored by the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) and the International Society for Aerosols in Medicine (ISAM), entitled "Regulatory and Patient Considerations for Inhalation Device Design, Development and Use." Key topics addressed at the workshop and presented here include patient-focused device design for orally inhaled products (OIPs), instructions for use (IFU), human factors, regulatory considerations in the United States and Europe, development of generic inhalers, quality-by-design, and change management of OIP devices. Workshop participants also identified several areas for further consideration and emphasized the need for increased focus on the patient to create therapeutic products (inclusive of device design, IFU, education, training) that support adherence with an individual patient's treatment regimen. Advances in patient-centric product development will require engagement and collaboration by industry, regulators, patients, physicians, and other stakeholders. The article includes summaries of presented talks as well as of panel and audience discussions.
Collapse
Affiliation(s)
- Nicolas Roche
- 1 Hôpital Cochin, AP-HP and University Paris Descartes (EA2511) , Sorbonne Paris Cité, Paris, France
| | | | | | | | - Deepika A Lakhani
- 5 US Food and Drug Administration, Center for Devices and Radiological Health , Silver Spring, Maryland
| | - Bhawana Saluja
- 6 US Food and Drug Administration, Center for Drug Evaluation and Research , Silver Spring, Maryland
| | - Janine Jamieson
- 7 Medicines and Healthcare Products Regulatory Agency , London, United Kingdom
| | - Andrew Dundon
- 8 GlaxoSmithKline , Ware, Hertfordshire, United Kingdom
| | | | - Susan Holmes
- 10 GlaxoSmtithKline, Research Triangle Park , North Carolina
| | | | - Myrna B Dolovich
- 12 Department of Medicine, McMaster University , Hamilton, Canada
| | | | | |
Collapse
|
2
|
O'Donnell KP, Williams RO. Pulmonary dispersion formulations: the impact of dispersed powder properties on pressurized metered dose inhaler stability. Drug Dev Ind Pharm 2012; 39:413-24. [PMID: 23216244 DOI: 10.3109/03639045.2012.664145] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Suspension-type metered dose inhaler formulations characteristically have a high degree of dispersion instability. This may occur as the result of any of a large number of formulation issues including phase separation, particle growth, agglomeration/flocculation, moisture ingress, and particle interactions with both the canister material and other particles. Many of these undesirable instabilities may arise as a result of the physical and chemical properties of the dispersed powder in the liquid propellant system. As such, this review provides a detailed understanding of the characteristics of the dispersed phase in the liquid propellant system necessary to ensure stability of the final formulation.
Collapse
Affiliation(s)
- Kevin P O'Donnell
- The University of Texas, College of Pharmacy, Division of Pharmaceutics, Austin, TX 78712, USA
| | | |
Collapse
|
3
|
Abstract
The pressurised metered-dose inhaler (pMDI) has now been available for 50 years. Once regarded as an inefficient and difficult-to-use device, the technology has evolved significantly over the last few years, particularly since the introduction of novel formulations containing hydrofluoroalkane (HFA) propellants. Many modern HFA pMDIs deposit drug more efficiently in the lungs, impact less forcefully on the back of the throat and feel less cold than their chlorofluorocarbon pMDI counterparts. An improved understanding of technical factors makes it possible to design HFA pMDIs to have specific spray properties, particularly in terms of fine particle dose and spray velocity. Device technology has also progressed with the introduction of compact and convenient breath-actuated, breath-coordinated and velocity-modifying devices, which help patients to achieve a reliable lung dose. Although it faces competition from dry powder inhalers and possibly from novel soft-mist inhalers containing liquid formulations, the rejuvenated HFA pMDI is a device with a significant future for asthma, chronic obstructive pulmonary disease and wider treatment indications.
Collapse
Affiliation(s)
- John Bell
- Stewart Erl Associates, Loughborough, UK.
| | | |
Collapse
|
4
|
Dhand R, Mercier E. Effective inhaled drug administration to mechanically ventilated patients. Expert Opin Drug Deliv 2006. [DOI: 10.1517/17425247.4.1.47] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|